- Home
- DMRC vs CGTX Comparison
DMRC vs CGTX Comparison
Compare DMRC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRC | CGTX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DMRC | CGTX |
|---|---|---|
| Price | $8.05 | $1.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $2.88 |
| AVG Volume (30 Days) | 138.4K | ★ 942.9K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,663,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.35 | $0.22 |
| 52 Week High | $48.32 | $3.83 |
Technical Indicators
Market Signals| Indicator | DMRC | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 50.66 |
| Support Level | $7.57 | $1.69 |
| Resistance Level | $9.64 | $1.76 |
| Average True Range (ATR) | 0.58 | 0.11 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 35.27 | 58.33 |
Price Performance
Historical ComparisonAbout DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.